Compare Medtronic PLC (MDT) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Altria Group Inc — how do they compare? Medtronic PLC trades at $82.8 (market cap $106.61B), while Altria Group Inc trades at $73.85 (market cap $124.67B). The key difference: Altria Group Inc is the larger of the two by market cap, and Altria Group Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.
| MDT | MO | |
|---|---|---|
Market Cap | $106.61B | $124.67B |
Sector | Health | Consumer Staples |
52-Week High | $105.35 | $74.66 |
52-Week Low | $73.75 | $54.72 |
Enterprise Value | $125.36B | $145.75B |
Dividend Yield | 3.46% | 5.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Altria (MO) trades at $74.14, down slightly by 0.09% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 39.52% net income margin and consistent dividend payments, including a recent $1.06 dividend declared for July 2026. Revenue remains stable around $20.1B for 2025, though net income dipped to $6.95B from prior peaks. Analyst consensus is predominantly bullish with 16 buys and a $71.00 price target.
Outlook: MO offers a high-yield dividend appeal and defensive positioning amid market volatility, but faces risks from declining smoking trends and regulatory pressures. Earnings beats in recent quarters provide support, though debt levels and competitive shifts in nicotine products warrant caution for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
